The literature cluster reveals a convergent effort to move dementia research beyond single-disease, single-modality paradigms toward integrated, precision-based frameworks for risk stratification and diagnosis. One major axis is the emergence of plasma-based, AI-driven multi-protein classifiers—exemplified by GPND-AI, a 15-protein panel measured via NULISA technology—that achieve high diagnostic accuracy (AUC 0.955, 92.3% accuracy) in differentiating Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and dementia with Lewy bodies, while also predicting mixed/co-existing pathologies. External validation against neuropathology-confirmed diagnoses at Banner Sun Health Research Institute underscores a broader trend of rigorous, gold-standard validation as a prerequisite for translational readiness, signaling a shift from research biomarkers toward clinically deployable diagnostic tools capable of resolving differential diagnosis challenges that have historically required autopsy confirmation.
A second axis centers on cerebral small vessel disease and vascular contributions to cognitive decline, particularly in underrepresented populations. The Latin American Cohort Study addresses a critical evidence gap by characterizing white matter hyperintensities, hypertension, smoking, and cardiometabolic risk profiles as modifiable correlates of cognitive impairment across diagnostic groups (including Alzheimer's disease and frontotemporal dementia, the latter showing comparatively lower small vessel disease burden). This work directly informs region-specific dementia prevention strategies, reflecting a broader movement toward population-tailored, modifiable-risk-factor interventions rather than uniform global guidelines.
A third thematic strand concerns resilience and reserve mechanisms that decouple pathology from clinical expression. The "super mover" phenotype—defined by exceptional gait speed in the oldest-old—demonstrates preserved hippocampal volume, slower memory and non-memory cognitive decline, and 51% lower risk of incident cognitive impairment, with effects attributed to functional and behavioral reserve rather than amyloid-related pathology. This positions gait speed as an accessible, modifiable screening and intervention target for cognitive aging, paralleling cellular-level aging models (replicative senescence in patient-derived fibroblasts from Alzheimer's dementia patients versus healthy controls) that probe transcriptomic signatures of resilience and vulnerability at the molecular level.
Collectively, these threads point toward a maturing field integrating molecular diagnostics, vascular/metabolic risk modeling, and functional reserve biomarkers into a multi-layered approach to neurodegenerative disease—spanning differential diagnosis, prevention, and mechanistic understanding of who remains resilient versus who declines.